PT2114873E - Ligandos para imagiologia de inervação cardíaca - Google Patents
Ligandos para imagiologia de inervação cardíaca Download PDFInfo
- Publication number
- PT2114873E PT2114873E PT78697174T PT07869717T PT2114873E PT 2114873 E PT2114873 E PT 2114873E PT 78697174 T PT78697174 T PT 78697174T PT 07869717 T PT07869717 T PT 07869717T PT 2114873 E PT2114873 E PT 2114873E
- Authority
- PT
- Portugal
- Prior art keywords
- compounds
- imaging
- cardiac innervation
- beta
- fluoropropoxy
- Prior art date
Links
- 230000000747 cardiac effect Effects 0.000 title abstract 3
- 230000030214 innervation Effects 0.000 title abstract 3
- 238000003384 imaging method Methods 0.000 title abstract 2
- ZYULQCDNUYJBRI-UHFFFAOYSA-N 2-[[3-bromo-4-(3-fluoropropoxy)phenyl]methyl]guanidine Chemical compound NC(=N)NCC1=CC=C(OCCCF)C(Br)=C1 ZYULQCDNUYJBRI-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 229930194542 Keto Natural products 0.000 abstract 1
- 238000012879 PET imaging Methods 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001743 benzylic group Chemical group 0.000 abstract 1
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical group OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012216 imaging agent Substances 0.000 abstract 1
- 125000000468 ketone group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 238000009206 nuclear medicine Methods 0.000 abstract 1
- 238000012636 positron electron tomography Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
- C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
- C07C215/60—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
- C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/06—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nuclear Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87721106P | 2006-12-26 | 2006-12-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2114873E true PT2114873E (pt) | 2013-05-06 |
Family
ID=39307501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT78697174T PT2114873E (pt) | 2006-12-26 | 2007-12-21 | Ligandos para imagiologia de inervação cardíaca |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US8491868B2 (enExample) |
| EP (5) | EP2474524A3 (enExample) |
| JP (3) | JP5656408B2 (enExample) |
| KR (4) | KR101718160B1 (enExample) |
| CN (3) | CN110003079A (enExample) |
| AU (1) | AU2007339954B2 (enExample) |
| BR (1) | BRPI0722082A8 (enExample) |
| CA (2) | CA2673853C (enExample) |
| CO (1) | CO6231002A2 (enExample) |
| DK (3) | DK2474523T3 (enExample) |
| ES (3) | ES2804801T3 (enExample) |
| IL (3) | IL199563A (enExample) |
| MX (2) | MX367292B (enExample) |
| PL (1) | PL2114873T3 (enExample) |
| PT (1) | PT2114873E (enExample) |
| RU (1) | RU2506256C2 (enExample) |
| SG (1) | SG177918A1 (enExample) |
| TW (2) | TWI618544B (enExample) |
| WO (1) | WO2008083056A2 (enExample) |
| ZA (1) | ZA200904828B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| JP5656408B2 (ja) * | 2006-12-26 | 2015-01-21 | ランセウス メディカル イメージング， インコーポレイテッド | 心臓の神経支配を画像化するためのリガンド |
| CN102858752B (zh) | 2010-02-08 | 2018-10-16 | 兰休斯医疗成像公司 | 用于合成显像剂和其中间体的方法和装置 |
| RU2710736C2 (ru) | 2010-05-11 | 2020-01-10 | Лантеус Медикал Имэджинг, Инк. | Композиции, способы и системы для синтеза и применение визуализирующих средств |
| US9301962B2 (en) | 2010-05-14 | 2016-04-05 | Baylor College Of Medicine | Male contraceptive compositions and methods of use |
| CA2799403C (en) | 2010-05-14 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating leukemia |
| BR112012029005A2 (pt) | 2010-05-14 | 2016-07-26 | Dana Farber Cancer Inst Inc | composições e métodos de tratamento de neoplasia, doença inflamatória e outros distúrbios |
| AR086113A1 (es) | 2011-04-30 | 2013-11-20 | Abbott Lab | Isoxazolinas como agentes terapeuticos |
| KR102527562B1 (ko) | 2011-09-09 | 2023-05-03 | 랜티우스 메디컬 이메징, 인크. | 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템 |
| BR112014024997B1 (pt) | 2012-04-10 | 2021-03-09 | Lantheus Medical Imaging, Inc. | métodos de síntese radiofarmacêutica |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| US20150246142A1 (en) * | 2012-09-25 | 2015-09-03 | The Regents Of The University Of Michigan | Imaging agents |
| EP2948045B1 (en) | 2013-01-24 | 2022-04-13 | Tylerton International Holdings Inc. | Body structure imaging |
| US20150366523A1 (en) * | 2013-01-24 | 2015-12-24 | Shlomo Ben-Haim | Neuronal imaging and treatment |
| CN105163657A (zh) * | 2013-03-11 | 2015-12-16 | 泰勒顿国际控股公司 | 自主神经系统建模及其用途 |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| US20160220835A1 (en) * | 2013-09-08 | 2016-08-04 | Tylerton International Inc. | Apparatus and methods for diagnosis and treatment of patterns of nervous system activity affecting disease |
| CN105849110B (zh) | 2013-11-08 | 2019-08-02 | 达纳-法伯癌症研究所有限公司 | 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法 |
| WO2015104672A2 (en) | 2014-01-10 | 2015-07-16 | Tylerton International Holdings Inc. | Detection of scar and fibrous cardiac zones |
| JP2017504651A (ja) | 2014-01-31 | 2017-02-09 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | ジアゼパン誘導体の使用 |
| WO2015117053A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| MX377534B (es) | 2014-02-28 | 2025-03-10 | Tensha Therapeutics Inc | Compuestos para usarse en el tratamiento de hiperinsulinemia. |
| EP3174464A4 (en) | 2014-07-30 | 2018-08-29 | Navix International Limited | Registering nuclear medicine data |
| BR112017002369A2 (pt) | 2014-08-08 | 2017-12-05 | Dana Farber Cancer Inst Inc | derivados de diazepana e usos dos mesmos |
| EP3177147A4 (en) | 2014-08-08 | 2018-01-24 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS |
| CN108472300A (zh) | 2015-09-11 | 2018-08-31 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| AU2016319785C1 (en) | 2015-09-11 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | Acetamide thienotriazolodiazepines and uses thereof |
| KR20180081809A (ko) | 2015-11-25 | 2018-07-17 | 다나-파버 캔서 인스티튜트 인크. | 2가 브로모도메인 억제제 및 그의 용도 |
| CN107892651A (zh) * | 2017-11-29 | 2018-04-10 | 陕西慧康生物科技有限责任公司 | 一种合成dl‑盐酸麻黄碱的方法 |
| US20210379210A1 (en) * | 2018-10-15 | 2021-12-09 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa1 receptor |
| EP3682906A1 (en) * | 2019-01-17 | 2020-07-22 | Julius-Maximilians-Universität Würzburg | Compound targeting norepinephrine transporter |
| CN109748825B (zh) * | 2019-02-01 | 2022-02-18 | 原子高科股份有限公司 | 一种18f标记的胍甲基取代苯类似物及其应用 |
| KR102690858B1 (ko) | 2020-07-14 | 2024-08-02 | 한국과학기술원 | 이산화탄소와 개미산만으로 성장 가능한 재조합 미생물 및 상기 재조합 미생물을 이용하여 유용물질을 제조하는 방법 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6012A (en) * | 1849-01-09 | Lithographing co | ||
| FR1010218A (fr) | 1949-02-10 | 1952-06-09 | American Cyanamid Co | Perfectionnements aux sels de guanidine |
| GB1215255A (en) | 1968-03-13 | 1970-12-09 | Pfizer & Co C | Halophenylalkylguanidine compounds |
| US4094881A (en) | 1976-03-10 | 1978-06-13 | Smithkline Corporation | Process for preparing triazolethiols |
| US4275074A (en) | 1979-03-09 | 1981-06-23 | Graham J. Dobbie | Catecholamine treatment of ocular hypertension |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4258188A (en) * | 1980-02-04 | 1981-03-24 | American Home Products Corporation | 2-(1-Piperazinyl)-cycloheptimidazole derivatives |
| US4622217A (en) * | 1984-04-27 | 1986-11-11 | The Regents Of The University Of Michigan | I-4-amino-3-iodobenzylguanidine as imaging and therapeutic agent |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4886499A (en) | 1986-12-18 | 1989-12-12 | Hoffmann-La Roche Inc. | Portable injection appliance |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| EP0288284A3 (en) * | 1987-04-24 | 1990-07-25 | King Faisal Specialist Hospital And Research Centre | Method of producing iodine 124 and meta-iodobenzylguanidine containing iodine 124 |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5674865A (en) * | 1991-10-18 | 1997-10-07 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| TW279864B (enExample) * | 1993-02-19 | 1996-07-01 | Janssen Pharmaceutica Nv | |
| US5879657A (en) * | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| EP0639573A1 (de) * | 1993-08-03 | 1995-02-22 | Hoechst Aktiengesellschaft | Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| DE69635460T2 (de) | 1995-06-26 | 2006-08-10 | Chelator Llc, Concord | Methode zur Hemmung des Wachstums von Bakterien oder Pilzen mit einem Komplexbildner |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| TW499412B (en) | 1996-11-26 | 2002-08-21 | Dimensional Pharm Inc | Aminoguanidines and alkoxyguanidines as protease inhibitors |
| US6130231A (en) | 1996-11-27 | 2000-10-10 | Dupont Pharmaceuticals | Integrin receptor antagonists |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| WO1999018053A1 (en) * | 1997-10-02 | 1999-04-15 | The University Of Western Ontario | Preparation of radiolabelled haloaromatics via polymer-bound intermediates |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| AU3406599A (en) | 1998-04-09 | 1999-11-01 | Institut Fur Diagnostikforschung Gmbh An Der Freien Universitat Berlin | Novel benzyl guanidine derivatives for therapy and (in-vivo) and (in-vitro) diagnosis |
| AU5671699A (en) | 1998-08-14 | 2000-03-06 | Smithkline Beecham Corporation | Grp receptor ligands |
| HK1047694A1 (zh) | 1998-12-18 | 2003-03-07 | 杜邦药品公司 | 玻连蛋白受体拮抗剂药物 |
| US6656448B1 (en) | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| GB0019357D0 (en) | 2000-08-07 | 2000-09-27 | Melacure Therapeutics Ab | Novel phenyl guanidines |
| DE10114561A1 (de) | 2001-03-24 | 2002-09-26 | Wella Ag | Verwendung von Mitteln enthaltend Kreatin, Kreatin und/oder deren Derivaten zur Verstärkung und Strukturverbesserung von keratinischen Fasern |
| US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
| AU2003263216A1 (en) | 2002-08-17 | 2004-03-11 | Nycomed Gmbh | Benzonaphthyridines with PDE 3/4 inhibiting activity |
| AU2003298582A1 (en) | 2002-09-17 | 2004-05-13 | Isis Pharmaceuticals, Inc. | Therapeutic guanidines |
| EP1641493A4 (en) * | 2003-06-30 | 2007-10-31 | Merck & Co Inc | RADIOACTIVELY MARKED CANNABINOID-1 RECEPTOR MODULATORS |
| CN101137326B (zh) * | 2003-12-01 | 2010-10-20 | 医疗物理有限公司 | 肾上腺素能成像剂和肾上腺素能干扰剂的应用及相关试剂盒 |
| WO2005095345A2 (en) * | 2004-03-23 | 2005-10-13 | Achillion Pharmaceuticals, Inc. | Heteroaryl guanidines as inhibitors of viral replication |
| JP4842123B2 (ja) | 2004-05-28 | 2011-12-21 | 浜松ホトニクス株式会社 | 放射性チロシン誘導体、その製造方法、放射性チロシン誘導体からなるポジトロンイメージング用標識剤及び腫瘍の悪性度評価薬剤並びに腫瘍の検出方法 |
| JP2008513533A (ja) | 2004-09-23 | 2008-05-01 | ゲルベ | Ｃｅｓｔイメージング用の造影剤封入システム |
| US20060083681A1 (en) | 2004-10-18 | 2006-04-20 | Ajay Purohit | Compounds for myocardial perfusion imaging |
| US7534418B2 (en) * | 2004-12-10 | 2009-05-19 | The Regents Of The University Of Michigan | Imaging agents |
| GB0512770D0 (en) | 2005-06-23 | 2005-07-27 | Hammersmith Imanet Ltd | Imaging compounds |
| JP2010513238A (ja) | 2006-12-13 | 2010-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | 微量アミン関連受容体（ｔａａｒ）に対するリガンドとしての新規２−イミダゾール |
| GB0625523D0 (en) | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
| JP5656408B2 (ja) | 2006-12-26 | 2015-01-21 | ランセウス メディカル イメージング， インコーポレイテッド | 心臓の神経支配を画像化するためのリガンド |
| WO2008082305A1 (en) | 2006-12-28 | 2008-07-10 | Raufoss Technology As | Control arm |
| WO2008115593A1 (en) | 2007-03-21 | 2008-09-25 | The University Of Montana | 1-[(2'-substituted)-piperazin-1'-yl]-isoquinolines as norepinephrine transporter inhibitor therapeutics and positron emission tomography imaging agents |
| RU2528340C2 (ru) | 2007-10-18 | 2014-09-10 | Бёрингер Ингельхайм Интернациональ Гмбх | ПОЛУЧЕНИЕ ДИГИДРОТИЕНО[3,2-d]ПИРИМИДИНОВ И ПРОМЕЖУТОЧНЫХ ПРОДУКТОВ, ПРИМЕНЯЮЩИХСЯ ДЛЯ ИХ СИНТЕЗА |
| WO2010015340A1 (en) | 2008-08-06 | 2010-02-11 | Bayer Schering Pharma Aktiengesellschaft | Daa-pyridine as peripheral benzodiazepine receptor ligand for diagnostic imaging and pharmaceutical treatment |
| GB0906274D0 (en) | 2009-04-09 | 2009-05-20 | Ge Healthcare Ltd | Imaging the central nervous system |
| US9687571B2 (en) | 2009-04-15 | 2017-06-27 | Lantheus Medical Imaging, Inc. | Stabilization of radiopharmaceutical compositions using ascorbic acid |
| CN101555232B (zh) | 2009-05-21 | 2011-01-05 | 北京师范大学 | 氟-18标记哒嗪酮类化合物及制备方法和应用 |
| WO2011005322A2 (en) | 2009-07-08 | 2011-01-13 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
| CN102858752B (zh) | 2010-02-08 | 2018-10-16 | 兰休斯医疗成像公司 | 用于合成显像剂和其中间体的方法和装置 |
| RU2710736C2 (ru) | 2010-05-11 | 2020-01-10 | Лантеус Медикал Имэджинг, Инк. | Композиции, способы и системы для синтеза и применение визуализирующих средств |
| KR102527562B1 (ko) | 2011-09-09 | 2023-05-03 | 랜티우스 메디컬 이메징, 인크. | 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템 |
| EP2671575A1 (en) | 2012-06-04 | 2013-12-11 | Universität Regensburg | Ras inhibitors |
| JP2017131851A (ja) | 2016-01-29 | 2017-08-03 | 日本特殊陶業株式会社 | マイクロ波加熱用触媒材料、マイクロ波加熱用触媒体、及び、その製造方法 |
-
2007
- 2007-12-21 JP JP2009544215A patent/JP5656408B2/ja active Active
- 2007-12-21 DK DK12152815.2T patent/DK2474523T3/da active
- 2007-12-21 MX MX2014010520A patent/MX367292B/es unknown
- 2007-12-21 CA CA2673853A patent/CA2673853C/en active Active
- 2007-12-21 PT PT78697174T patent/PT2114873E/pt unknown
- 2007-12-21 EP EP12152816A patent/EP2474524A3/en active Pending
- 2007-12-21 TW TW105113601A patent/TWI618544B/zh not_active IP Right Cessation
- 2007-12-21 SG SG2011095601A patent/SG177918A1/en unknown
- 2007-12-21 ES ES12152815T patent/ES2804801T3/es active Active
- 2007-12-21 RU RU2009128591/04A patent/RU2506256C2/ru active
- 2007-12-21 CN CN201910053427.0A patent/CN110003079A/zh active Pending
- 2007-12-21 KR KR1020097015613A patent/KR101718160B1/ko not_active Expired - Fee Related
- 2007-12-21 EP EP12152818A patent/EP2474526A3/en not_active Withdrawn
- 2007-12-21 KR KR1020147032350A patent/KR20140140134A/ko not_active Ceased
- 2007-12-21 AU AU2007339954A patent/AU2007339954B2/en active Active
- 2007-12-21 DK DK07869717.4T patent/DK2114873T3/da active
- 2007-12-21 ES ES07869717T patent/ES2405655T3/es active Active
- 2007-12-21 EP EP12152817.8A patent/EP2474525B1/en active Active
- 2007-12-21 PL PL07869717T patent/PL2114873T3/pl unknown
- 2007-12-21 CN CN200780051773.0A patent/CN101687780B/zh not_active Expired - Fee Related
- 2007-12-21 BR BRPI0722082A patent/BRPI0722082A8/pt not_active Application Discontinuation
- 2007-12-21 ES ES12152817T patent/ES2805286T3/es active Active
- 2007-12-21 TW TW096149600A patent/TWI549692B/zh not_active IP Right Cessation
- 2007-12-21 KR KR1020177024416A patent/KR20170102580A/ko not_active Ceased
- 2007-12-21 CN CN201510856954.7A patent/CN105622463B/zh not_active Expired - Fee Related
- 2007-12-21 DK DK12152817.8T patent/DK2474525T3/da active
- 2007-12-21 MX MX2009007018A patent/MX2009007018A/es active IP Right Grant
- 2007-12-21 EP EP12152815.2A patent/EP2474523B1/en active Active
- 2007-12-21 US US12/448,575 patent/US8491868B2/en active Active
- 2007-12-21 EP EP07869717A patent/EP2114873B1/en active Active
- 2007-12-21 CA CA2984226A patent/CA2984226C/en active Active
- 2007-12-21 KR KR1020167010430A patent/KR101810348B1/ko not_active Expired - Fee Related
- 2007-12-21 WO PCT/US2007/088500 patent/WO2008083056A2/en not_active Ceased
-
2009
- 2009-06-25 IL IL199563A patent/IL199563A/en active IP Right Grant
- 2009-07-09 ZA ZA2009/04828A patent/ZA200904828B/en unknown
- 2009-07-22 CO CO09076173A patent/CO6231002A2/es active IP Right Grant
-
2013
- 2013-01-24 IL IL224396A patent/IL224396B/en active IP Right Grant
- 2013-06-12 US US13/916,205 patent/US10010631B2/en active Active
-
2014
- 2014-07-25 JP JP2014152244A patent/JP6021860B2/ja active Active
-
2016
- 2016-04-21 JP JP2016085372A patent/JP2016183164A/ja active Pending
-
2017
- 2017-08-07 IL IL253885A patent/IL253885A0/en unknown
-
2018
- 2018-05-22 US US15/986,680 patent/US11241509B2/en active Active
-
2022
- 2022-01-28 US US17/587,454 patent/US12324845B2/en active Active
-
2025
- 2025-01-17 US US19/027,961 patent/US20250161500A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2114873E (pt) | Ligandos para imagiologia de inervação cardíaca | |
| RU2386626C2 (ru) | 1a, 5a-ТЕТРАГИДРО-S-ТИАЦИКЛОПРОПА[a]ПЕНТАЛЕНЫ:ТРИЦИКЛИЧЕСКИЕ ПРОИЗВОДНЫЕ ТИОФЕНА В КАЧЕСТВЕ АГОНИСТОВ РЕЦЕПТОРОВ S1P1/EDG1 | |
| FR20C1018I1 (fr) | Composition pharmaceutique comprenant du glycopyrrolate et un agoniste du récepteur beta2 adrénergique | |
| ES2526544T3 (es) | Derivado de ácido aminocarboxílico y uso médico del mismo | |
| CY1111310T1 (el) | Ενωσεις για την αγωγη μεταβολικων διαταραχων | |
| NZ592258A (en) | Pesticidal (hetero) arylpyrrolidines | |
| JP2004516293A5 (enExample) | ||
| RU2010107284A (ru) | Производные нафтиридина в качестве модуляторов калиевых каналов | |
| WO2004073611A3 (en) | Compounds for the treatment of metabolic disorders | |
| MX2010003603A (es) | Metodo para el tratamiento de enfermedades de riñon poliquisticas con derivados de ceramida. | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| MX2009003916A (es) | Compuestos heterociclicos utiles como agentes anabolicos para animales de ganado. | |
| MXPA05011592A (es) | Compuestos para el tratamiento de trastornos metabolicos. | |
| UA95613C2 (ru) | Соединения для лечения расстройсв метаболизма | |
| DE602004024382D1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| CO5180605A1 (es) | Compuestos de indol | |
| BRPI0409049A (pt) | métodos de preparação de um composto, composição e composição cristalina | |
| EP2518049A3 (en) | Aminoalcohol derivatives and their therapeutic use | |
| RU2384573C2 (ru) | Пиразол- и фенилпроизводные в качестве ингибиторов ppar | |
| MX2021013849A (es) | 4-[5-[(rac)-1-[5-(3-clorofenil)-3-isoxazolil]etoxi]-4-metil-4h-1, 2,4-triazol-3-il]piridina para usar en la prevencion y/o el tratamiento del dolor en un animal. | |
| EP2048148A4 (en) | METHYLAQUOCOBYRINIC ACID DERIVATIVE, ALKYLATION COMPOSITION AND METHOD FOR DETACHING HARMFUL COMPOUNDS USING THE COMPOSITION | |
| CY1114152T1 (el) | Ν-[3-βρωμο-4-(3-[18f]φθοροπροποξυ)-βενζυλο]-γουανιδινη για απεικονιση της καρδιακης εννευρωσης | |
| KR910007875A (ko) | 도파민 길항제로서의 벤질피롤리딘 유도체 | |
| GEP20094787B (en) | Pharmaceutical composition comprising a 1-(3-chloro-phenyl)-3-alkyl piperazine for treating appetite disorder | |
| WO2007076601B1 (en) | Imaging of d2high receptors using radiolabelled (-)- quinpirole and analogs thereof |